Industry News

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ I.V., a biosimilar to Stelara® (ustekinumab injection) and Stelara® I.V. (ustekinumab for injection, solution for intravenous infusion). The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October.

AstraZeneca has announced a historic agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients while maintaining the nation’s leadership in biopharmaceutical innovation.

At a White House event, AstraZeneca CEO Pascal Soriot joined President Trump and senior officials to confirm that the company has voluntarily met all four requests outlined in the President’s July 31 letter. The agreement enables American patients to access AstraZeneca medicines at prices aligned with those in other wealthy nations.

NATCO Pharma Limited has announced a significant legal victory in its ongoing patent dispute with Roche, enabling the company to launch its generic version of Risdiplam, a drug used in the treatment of Spinal Muscular Atrophy (SMA), in India.